首页 > 市场调查报告书 > 製药

个人化医学

市场调查报告书

商品编码

1402610

伴同性诊断市场：依技术类型、按应用、按最终用户、按地区

Companion Diagnostics Market, By Technology Type (Real Time-Polymerase Chain Reactions, Gene Sequencing, Fluorescence in situ Hybridization, and Others) By Application, By End User, By Region

出版日期: 2023年12月21日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球伴同性诊断市场规模为69.5亿美元，预计2030年将达156.3亿美元，2023年至2030年复合年增长率为12.3%。

报告范围		报告详情
基准年	2022年	2023年市场规模	69.5亿美元
实际资料	2018-2021	预测期	2023-2030
预测期复合年增长率	12.30%	2030年市场规模预测	156.3亿美元

图 1. 2023 年伴同性诊断的全球市场占有率(%)（按地区）

伴同性诊断是用于检测患者特定生物标记或基因的医疗设备，可以帮助确定哪些患者最适合特定治疗。这些诊断透过帮助医生选择适当的癌症和其他疾病的标靶治疗，在个体化医疗保健中发挥重要作用。伴同性诊断测试评估生物标记的表达，例如参与患者对特定药物反应的蛋白质、基因和染色体。透过分析此类生物标记的表达水平，这些测试可以帮助确定特定药物对于患有特定疾病的特定患者或患者群体是否安全有效。这确保了只有合适的患者才能接受专门的治疗，从而改善治疗结果。

市场动态：

全球伴同性诊断市场的推动因素包括个人化医疗需求的不断增长、分子诊断的增长、新的标靶治疗和伴同性诊断的核准不断增加、技术进步以及癌症和其他慢性病的流行和流行。在费率方面。然而，这些分子诊断测试的开发和商业化面临高昂的价格压力和监管麻烦，这可能会限制市场成长。该市场的主要机会包括免疫治疗生物标记和伴同性诊断的开发、非肿瘤疾病关键应用的开发以及体外诊断（IVD）公司和药品製造商之间的精准医疗联盟，更加关注伴同性诊断的开发新兴市场的发展，以及采用次世代定序(NGS) 等先进技术进行生物标记检测。

本研究的主要特点

我们详细分析了全球伴同性诊断市场，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模。
它揭示了不同细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
该报告根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球伴同性诊断市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
伴同性 Diagnostics 全球市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过分析全球伴同性诊断市场时所使用的各种策略矩阵，将有助于相关人员做出决策。

北美洲
美国
加拿大
欧洲
德国
英国
西班牙
法国
义大利
俄罗斯
其他欧洲国家
亚太地区
中国
印度
日本
澳洲
韩国
ASEAN
其他亚太地区
拉丁美洲
巴西
阿根廷
墨西哥
其他拉丁美洲
中东
海湾合作委员会国家
以色列
其他中东地区
非洲
南非
北非
中部非洲

第9章竞争形势

公司简介
- F.Hoffmann-La Roche AG
- Agilent Technologies, Inc
- QIAGEN NV
- Abbott Laboratories, Inc.
- Almac Group
- Danaher Corporation
- Illumina, Inc
- bioMerieux SA
- Myriad Genetics, Inc
- Sysmex Corporation
- Thermo Fisher Scientific Inc
- Abnova Corporation
- Guardant Health, Inc.
- Icon Plc
- Biogenex Laboratories, Inc
分析师观点

第10章

参考
调查方法
关于出版商

简介目录

Product Code: CMI109

Global companion diagnostics market size is estimated to be valued at US$ 6.95 Bn in 2023 and is expected to reach US$ 15.63 Bn by 2030, exhibiting a compound annual growth rate (CAGR) of 12.3 % from 2023 to 2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 6.95 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	12.30%	2030 Value Projection:	US$ 15.63 Bn

Figure1. Global Companion Diagnostics Market Share (%), By Region, 2023

Companion diagnostics are medical devices that are used to detect specific biomarkers or genes in patients that help determine which patients are most suitable candidates for a particular therapy. These diagnostics play an important role in personalized healthcare by helping physicians select appropriate targeted treatment options for cancer and other diseases. Companion diagnostics tests evaluate the expression of biomarkers, such as proteins, genes or chromosomes that plays a role in a patient's response to a specific drug. By analyzing the expression levels of such biomarkers, these tests help to identify whether a particular drug would be safe and effective for a specific patient or set of patients with a given disease. This enables better therapeutic outcomes by ensuring only suitable patients receive specialized treatments.

Market Dynamics:

Global companion diagnostics market is driven by rising demand for personalized medicine, growth in molecular diagnostics, increasing approvals of new targeted therapies & companion diagnostics, technological advancements, and growing incidence and prevalence of cancer, and other chronic diseases. However, the market growth can be restricted by high pricing pressure and regulatory hassles that are involved in developing and commercializing these molecular diagnostic tests. Key opportunities in this market include developing biomarkers and companion diagnostics for immunotherapies, expanding applications in non-oncology diseases, precision medicine collaborations between In vitro diagnostics (IVD) companies and drug makers, growing focus on companion diagnostic development in emerging markets, and adoption of advanced technologies like Next-generation sequencing (NGS) for biomarker detection.

Key features of the study:

This report provides in-depth analysis of the global companion diagnostics market, and provides market size (US$ Bn)and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global companion diagnostics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc., bioMerieux SA, Myriad Genetics, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Health, Inc., Icon Plc., and Biogenex Laboratories, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion diagnostics market

Detailed Segmentation:

Global Companion Diagnostics Market, By Technology Type
- Real Time-Polymerase Chain Reactions (PCR
- Gene Sequencing
- Fluorescence in situ Hybridization
- Others
Global Companion Diagnostics Market, By Application
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Diseases
- Others
Global Companion Diagnostics Market, By End User
- Hospitals
- Research Laboratories
- Biopharmaceutical companies
- Others
Global Companion Diagnostics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in Global Companion Diagnostics Market:
- F.Hoffmann-La Roche AG
- Agilent Technologies, Inc.
- QIAGEN N.V
- Abbott Laboratories, Inc.
- Almac Group
- Danaher Corporation
- Illumina, Inc.
- bioMerieux SA
- Myriad Genetics, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Abnova Corporation
- Guardant Health, Inc.
- Icon Plc.
- Biogenex Laboratories, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Technology Type
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing number of cancer patients
- Complexity of Integration
- Emerging markets
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Companion Diagnostics Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Companion Diagnostics Market, By Technology Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Real Time-Polymerase Chain Reactions (PCR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Gene Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Fluorescence in situ Hybridization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Companion Diagnostics Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Neurological Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Companion Diagnostics Market, By End User, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Research Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Biopharmaceutical companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Companion Diagnostics Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2019 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
South Africa
North Africa
Central Africa

9. Competitive Landscape

Company Profiles
- F.Hoffmann-La Roche AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Agilent Technologies, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- QIAGEN N.V
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Abbott Laboratories, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Almac Group
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Danaher Corporation
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Illumina, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- bioMerieux SA
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Myriad Genetics, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sysmex Corporation
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Thermo Fisher Scientific Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Abnova Corporation
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Guardant Health, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Icon Plc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Biogenex Laboratories, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analysts' Views

10. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

伴同性诊断市场：依技术类型、按应用、按最终用户、按地区